

# Burcin Ã–zdirik

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6647424/publications.pdf>

Version: 2024-02-01

17  
papers

181  
citations

1307594

7  
h-index

1125743

13  
g-index

17  
all docs

17  
docs citations

17  
times ranked

267  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. <i>Hepatic Oncology</i> , 2020, 7, HEP20.   | 4.2 | 30        |
| 2  | The Role of Microbiota in Primary Sclerosing Cholangitis and Related Biliary Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6975.  | 4.1 | 22        |
| 3  | Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 652172.  | 4.8 | 21        |
| 4  | Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions. <i>Neuroendocrinology</i> , 2021, 111, 217-236.   | 2.5 | 17        |
| 5  | Primary Neuroendocrine Neoplasms of the Breast: Case Series and Literature Review. <i>Cancers</i> , 2020, 12, 733.   | 3.7 | 17        |
| 6  | From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1492.   | 4.1 | 16        |
| 7  | Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma. <i>Medicine (United States)</i> , 2021, 100, e26377.   | 1.0 | 10        |
| 8  | In Vivo Models for Cholangiocarcinoma—What Can We Learn for Human Disease?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4993.   | 4.1 | 8         |
| 9  | Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2881.   | 2.4 | 8         |
| 10 | The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8569.  | 4.1 | 8         |
| 11 | PD-L1 “inhibitors in neuroendocrine neoplasia. <i>Medicine (United States)</i> , 2021, 100, e23835.  | 1.0 | 7         |
| 12 | Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies. <i>Journal of Clinical Medicine</i> , 2020, 9, 1647.  | 2.4 | 6         |
| 13 | A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report. <i>Molecular and Clinical Oncology</i> , 2020, 14, 20.   | 1.0 | 4         |
| 14 | Serum levels of miR-223 but not miR-21 are decreased in patients with neuroendocrine tumors. <i>PLoS ONE</i> , 2020, 15, e0244504.   | 2.5 | 3         |
| 15 | Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis. <i>Journal of Clinical Medicine</i> , 2022, 11, 2479.                                | 2.4 | 2         |
| 16 | A case report of an excellent response to interferon- $\beta$ in a patient with functional metastasized neuroendocrine tumor refractory to other treatments. <i>Medicine (United States)</i> , 2020, 99, e20820.                       | 1.0 | 1         |
| 17 | Low Serum Levels of Soluble Receptor Activator of Nuclear Factor $\kappa$ B Ligand (sRANKL) Are Associated with Metabolic Dysregulation and Predict Long-Term Mortality in Critically Ill Patients. <i>Diagnostics</i> , 2022, 12, 62. | 2.6 | 1         |